# A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.

> **NCT00249782** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 400 (actual)

## Conditions studied

- Rosacea

## Interventions

- **DRUG:** Vehicle control, 2x/day
- **DRUG:** ACZONE (dapsone) Gel, 5%, 2x/day
- **DRUG:** ACZONE (dapsone) Gel, 5%, 1x/day
- **DRUG:** MetroGel® (metronidazole gel), 1.0% 1x/day
- **DRUG:** ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)

## Key facts

- **NCT ID:** NCT00249782
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2011-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00249782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00249782, "A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00249782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*